aTYR PHARMA INC ATYR
- Market cap
- $15.4M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- Q2 FY26 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- Q2 FY26 missing
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −355.4%
aTYR PHARMA INC's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $353K | $0 | $235K | $0 | $0 | $0 | $0 | $0 | $190K | $0 | $0 | n/a | |
| R&D | $10.3M+5% | $12.8M−15% | $13.4M+43% | $14M+42% | $14.8M+44% | $12.2M−4% | $11.8M−12% | $15.4M+10% | $22.1M+50% | $10.9M−11% | $7.3M−38% | $6.7M−56% |
| SG&A | $2.6M−27% | $3.2M−7% | $3.5M+3% | $3.3M−10% | $3.3M+26% | $3.6M+12% | $4M+13% | $4.9M+48% | $4.8M+44% | $3.9M+9% | $4.1M+4% | $4.1M−16% |
| −$12.6M−7% | −$16M+101% | −$16.6M+30% | −$17.3M+28% | −$18.1M+44% | −$15.8M−1% | −$15.8M−5% | −$20.3M+17% | −$26.7M+47% | −$14.8M−7% | −$11.4M−28% | −$10.9M−46% | |
| Net income | −$11.3M−14% | −$14.8M+96% | −$15.5M+30% | −$16.3M+32% | −$17.3M+52% | −$15M+1% | −$14.9M−4% | −$19.5M+20% | −$25.7M+49% | −$14M−7% | −$10.8M−28% | −$10.3M−47% |
| −$8.00−57% | −$10.00−4% | −$9.20−21% | −$9.20+5% | −$9.20+15% | −$7.20−28% | −$6.80−26% | −$8.80−4% | −$10.40+13% | −$5.60−22% | −$4.40−35% | −$4.40−50% | |
| 1.4M+102% | 1.5M+104% | 1.7M+58% | 1.8M+31% | 1.9M+31% | 2.1M+40% | 2.2M+31% | 2.3M+25% | 2.4M+28% | 2.5M+19% | 2.5M+13% | 2.5M+9% |
EPS, diluted: 7 periods, Q4 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 12 periods, Q4 FY14 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest aTYR PHARMA INC's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ATYRaTYR PHARMA INC | $15.4M | n/m | n/a | n/m | n/m | n/m | |
| NEPHNephros | $35.2M | 20.3× | 28.3× | 1.7× | +24% | 8.4% | |
| ATNMActinium Pharmaceuticals | $45M | 4.0× | 3.3× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.3M | 13.5× | 14.8× | 0.9× | +6% | 6.8% | |
| SPROSpero Therapeutics | $60.6M | 9.5× | 9.5× | 1.3× | −3% | 15.7% | |
| LFVNLifevantage | $73.5M | 14.7× | 19.4× | 0.4× | −20% | 2.8% | |
| ICCCImmucell | $95.9M | 132× | 44.1× | 3.1× | +8% | 2.6% | |
| KEQUKewaunee Scientific | $96.7M | 12.1× | 13.6× | 0.3× | +5% | 3.0% | |
| Peer median | $60.6M | 13.5× | 14.8× | 1.1× | +6% | 4.9% |
More on aTYR PHARMA INC
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .